MERCK AS NUMBER ONE: VITAL STATISTICS
Executive Summary
A synopsis of the areas in which Merck holds the top position in the drug industry. The information is taken from the Nov. 3 presentation by Merck Chairman Vagelos to the New York Society of Security Analysts. * World pharmaceutical market -- number one with a less than 5% total marketshare * U.S. pharmaceutical market -- sales leader for the ninth consecutive year and expecting to "substantially increase" its lead over runner-up Glaxo in 1988 * U.S. drug companies in Europe -- sales leader; plans to be the leading company in Europe by 1992 * Injectable antibiotics -- worldwide leader, Primaxin has surpassed Mefoxin, "for some years the world leader" * Compound annual return to shareholders (stock appreciation and dividends) -- during 1986-1988, 52%, "by far the best in our industry"
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth